JC polyomavirus (JCPyV) is the causative agent of the demyelinating disease of the central nervous system known as progressive multifocal leukoencephalopathy (PML), which occurs in immunocompromised patients. Moreover, patients treated with natalizumab for multiple sclerosis or Crohn disease can develop PML, which is then termed natalizumab-related PML. Because few drugs are currently available for treating PML, many antiviral agents are being investigated. It has been demonstrated that the topoisomerase I inhibitors topotecan and b-lapachone have inhibitory effects on JCPyV replication in IMR-32 cells. However, both of these drugs have marginal inhibitory effects on virus propagation in JC1 cells according to RT-PCR analysis. In the present study, the inhibitory effect of another topoisomerase I inhibitor, 7-ethy-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin (CPT11), was assessed by investigating viral replication, propagation, and viral protein 1 (VP1) production in cultured cells. JCPyV replication was assayed using real-time PCR combined with Dpn I treatment in IMR-32 cells transfected with JCPyV DNA. It was found that JCPyV replicates less in IMR-32 cells treated with CPT11 than in untreated cells. Moreover, CPT11 treatment of JCI cells persistently infected with JCPyV led to a dose-dependent reduction in JCPyV DNA and VP1 production. Additionally, the inhibitory effect of CPT11 was found to be stronger than those of topotecan and b-lapachone. These findings suggest that CPT11 may be a potential anti-JCPyV agent that could be used to treat PML.
PML. (2) . Topoisomerase I, which catalyzes the relaxation of supercoiled DNA both in vitro and in vivo, is required for DNA replication and RNA transcription (3) . CPT inhibits topoisomerase I by stabilizing cleavable complexes (4) , thus preventing DNA strand re-ligation. Collisions between cleavable complexes with replication or transcription machinery convert to irreversible covalent DNA damage, leading to cell cycle arrest and apoptosis, which are responsible for the cytotoxic activity of such drugs (5) .
Previous studies have reported that nucleoside analogues (6) , mefloquine (7) and topoisomerase I inhibitors (8, 9) are effective at inhibiting viral replication. Currently, no antiviral drugs are available for treating non-AIDS-related PML; however, possible new antiviral agents are being researched.
It has been reported that the topoisomerase I inhibitors CPT and topotecan can suppress JCPyV replication in human glioblastoma cells (8) . Moreover, our previous study demonstrated that the topoisomerase I inhibitors topotecan and b-lapachone have inhibitory effects on viral replication, propagation and VP1 production in IMR-32 and JCI cells (9) . However, topotecan reportedly causes severe cell toxicity in cell culture (8, 9) . Moreover, treatment with topotecan or b-lapachone results in marginal inhibition of viral propagation in JCI cells, which produce high titers of JCPyV, according to RT-PCR analysis (9) . In contrast, UV resonance Raman spectroscopy using oligonucleotides derived from the sequences of topoisomerase I-induced and CPT-enhanced cleavage sites in SV40 DNA showed differences in the interactions of CPT and CPT11 (10) . This report led us to seek other topoisomerase inhibitors of JCPyV, a synthesized CPT derivative that has been shown to be associated with inhibition of topoisomerase I.
In the present study, was assessed the inhibitory effect of CPT11 on JCPyV replication and propagation using IMR-32 and JCI cells, respectively. Production of the VP1 antigen in JCI cells upon treatment with CPT11 was also evaluated using western blot analysis and immunocytochemical staining. In addition, we compared the inhibitory effect of CPT11 on viral propagation in JCI cells with those of topotecan and b-lapachone.
MATERIALS AND METHODS
Cell lines, plasmid and compound IMR-32 and JCI cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% FBS as previously described (11) . M1-IMRb plasmid (12) was kindly provided by Dr Yogo (University of Tokyo). CPT11 was purchased from Abcam (Cambridge, MA, USA) and dissolved in water.
Quantification of cell proliferation
Concentrations of 5.0 Â 10 4 cells/well were treated with 0.01, 0.1 or 1.0 mM of CPT11 (IMR-32 cells), and 0.01, 0.03, 0.1, 0.3, 1.0, 3.0 or 10 mM of CPT11 (JCI cells). Cytotoxicity was assessed using a Cell Proliferation Kit I (MTT; Roche, IN, USA) by MTT assay as previously described (13) . Experiments were performed using four independent cultures.
DNA replication assay using RT-PCR
JCPyV DNA (1.0 mg) excised from a M1-IMRb plasmid with EcoRI was transfected into IMR-32 cells using FuGENE 6 transfection reagent (Roche), as previously described (13) . At 5 hr after transfection, the cells were treated with 0.01 or 0.1 mM of CPT11. At 72 hr after drug treatment, cellular and viral DNA were extracted from cell cultures using a QIAamp DNA Mini kit (Qiagen, Hilden, Germany). DNA replication analysis using RT-PCR combined with Dpn I treatment was performed as previously described (14, 15) . The extracted DNA (1.0 mg) was digested with Dpn I in a volume of 30 mL at 37°C overnight to remove input JCPyV DNA. After heat inactivation of Dpn I at 80°C for 20 min, 160 ng of digested DNA was used for RT-PCR analysis, which was performed using ABI PRISM 7900HI (Applied Biosystems, Foster City, CA, USA) according to a previously described method (13) . Data are shown as copy numbers per cell. Experiments were performed using three independent cultures.
RT-PCR quantification of JCPyV DNA Viral DNA was extracted from three independent JCI cell cultures 72 hr after treatment with 0.01, 0.03, 0.1, 0.3 or 1.0 mM of CPT11 to enable calculation of IC 50 , and 1.0 nM topotecan, 0.1 mM b-lapachone or 1.0 mM CPT11 for comparative experiments, using a QIAamp DNA Mini Kit (Qiagen). RT-PCR was performed to quantify JCPyV DNA, as previously described (16) . Data are shown as copy numbers per cell. Experiments were performed using three independent cultures.
Western blot analysis
Western blot analysis was performed to detect JCPyV VP1. Briefly, JCI cells were plated in 6-well plates and exposed 24 hr later to 0.01, 0.03, 0.1, 0.3 or 1.0 mM of CPT11. After 72 hr, the cells were harvested and washed twice with PBS. The harvested cells (2.0 Â 10 4 ) were lysed in 100 mL of SDS-PAGE sample buffer, after which CPT11 prevents JCPyV replication 20 mL of the sample was separated on a 12.5% SDS-PAGE gel and transferred to a PVDF membrane (BioRad, Hercules, CA, USA) using Trans-Blot SD Cell (BioRad). Non-specific reactions were blocked by overnight incubation of the membranes with PBS containing 3.0% non-fat milk. The membranes were then incubated with an anti-human polyomavirus JCPyV VP1 antibody (Abcam) at a dilution of 1:1000 in PBS containing 3.0% non-fat milk for 2 hr, and then with goat antimouse IgG H&L (HRP) at a dilution of 1:3000 in PBS containing 3.0% non-fat milk for 1 hr. Immunoreactive protein bands were visualized using Pierce Western Blotting Substrate Plus (Thermo Fisher Scientific, Tokyo, Japan) and an OptimaShot CL-420a chemiluminescence imaging system (Wako, Osaka, Japan).
Immunocytochemical staining JCI cells that had been cultured for 72 hr with 0.1 or 1.0 mM of CPT11 were washed twice with PBS. JCPyV VP1 antigen was then detected with an anti-human polyomavirus JCPyV VP1 antibody (Abcam), followed by labelling with a Histofine SAB-PO (MULTI) kit (Nichirei, Tokyo, Japan) and staining using a Peroxidase Stain DAB kit (Nacalai Tesque, Kyoto, Japan) according to a previous report (9, 17) . VP1-positive cells were counted under an Olympus microscope (Â200) in three fields per sample (positive 1000 cells). IMR-32 cells were included as a negative control.
Calculation of IC 50 and CC 50
IC50 and CC50 were calculated by dose-response curves using the standard function of GraphPad Prism 5 software (GraphPad Software, San Diego, CA, USA) (9) .
Statistical analysis
The significance of differences between groups was determined using a statistical program and Student's ttest (9) .
RESULTS

CPT11 prevents JCPyV replication in IMR-32 cells
The cytotoxicity of CPT11 was assessed by MTT assay. IMR-32 cells treated with 1.0 mM CPT11 had significantly lower absorbances than did the untreated cultures (P < 0.01) (Fig. 1a) . RT-PCR analysis combined with Dpn I treatment was used as a DNA replication assay to quantify JCPyV DNA. CPT11 was added to IMR-32 cells transfected with M1-IMRb at 0.01 or 0.1 mM, at which concentrations no cell toxicity had been detected. At 72 hr after drug treatment, total DNA was extracted from cells. RT-PCR demonstrated that the amount of JCPyV DNA in cells treated with 0.01 mM of CPT11 was only 30.8% of that of controls; this difference is significant (Fig. 1b) (P < 0.05). In contrast, the amount of JCPyV DNA in cells treated with 0.1 mM CPT11 was only 15.1% that of controls, a significant difference (Fig. 1b) (P < 0.05), suggesting that CPT11 prevents JCPyV replication in IMR-32 cells.
CPT11 suppresses JCPyV propagation in JCI cells
The cytotoxicity of JCI cells treated with 3.0 mM CPT11 was significantly higher than that of untreated cells (P < 0.01) (Fig. 2a) . JCI cells were treated with 0.1 or 1.0 mM of CPT11. At 72 hr after CPT11 treatment, the JCPyV DNA was determined by RT-PCR analysis. The amount of JCPyV DNA in cells treated with 0.1, 0.3 and 1.0 mM of CPT11 was 48.0%, 45.9% and 17.2% of that of controls (P < 0.05 at 0.3 mM, P < 0.01 at 0.1 and 1.0 mM) (Fig. 2b) . These results indicate that CPT11 significantly suppresses JCPyV propagation in JCI cells.
CPT11 suppresses VP1 production in JCI cells
VP1 is the major capsid protein that binds to cell receptors to produce infection (1). Western blot analysis (Fig. 3 ) and immunocytochemical staining (Fig. 4) were performed to examine VP1 production in JCI cells. For western blot analysis, JCI cells were exposed to various concentrations of CPT11 for 72 hr, after which expression of VP1was measured at the protein level. JCPyV VP1 was detected as a single band (42 kDa) in JCI cell lysates derived from all concentrations (Fig. 3) . CPT11 inhibits the expression of VP1 in JCI cells in a dosedependent manner. At 72 hr after drug treatment, JCPyV VP1 antigen was detected using immunocytochemical staining in JCI cells treated with 0.1 or 1.0 mM of CPT11, which had been shown to produce no cell toxicity. At 72 hr, the number of VP1-positive cells was 62.5% (0.1 mM) and 27.1% (1.0 mM) that of controls in CPT11-treated cells (Fig. 5) ; these differences are significant (P < 0.05 at 0.1 mM and P < 0.01 at 1.0 mM). JCPyVpositive cells were not detected in IMR-32 cells. These results indicate that CPT11 dose-dependently inhibits production of the JCPyV VP1 antigen in JCI cells.
CPT11 suppresses viral production more strongly than do topotecan or b-lapachone As a comparative experiment, the inhibitory effect of CPT11 on viral propagation in JCI cells was compared with that of topotecan or b-lapachone. The concentrations of topotecan, b-lapachone and CPT11 were 1.0 nM, 0.1 mM and 1.0 mM, respectively; these are effective doses. The JCPyV copy number in CPT11-treated cells was 49.1% and 47.5% of those of topotecan and b-lapachone-treated cells, respectively (Fig. 6) ; these differences are statistically significant (P < 0.05). The amounts of JCPyV DNA were similar in topotecan-treated and b-lapachone-treated cells (Fig. 6) , indicating that the inhibitory effect of CPT11 is stronger than those of topotecan and b-lapachone.
IC 50 s and CC 50 s of topoisomerase inhibitor
The IC 50 of CPT11 on JCPyV propagation was 73.4 nM, whereas the CC 50 of CPT11 in JCI cells was 10.7 mM. The (Fig. 2b) . Data are shown as mean AE SD.
IC 50 s of CPT11 was much lower than the CC 50 s on JCPyV propagation in JCI cells.
DISCUSSION
In immunocompromised patients with PML, JCPyV propagates in oligodendrocytes in the central nervous system and then induces myelin loss. This also occurs in patients who have been treated with natalizumab for MS or Crohn disease and have natalizumab-related PML (2). This adverse effect limits the use of natalizumab therapy. Previous studies have reported that the topoisomerase I inhibitors CPT, topotecan and b-lapachone can suppress JCPyV replication in cultures of cells (8, 9) , suggesting that other topoisomerase I inhibitors may potentially serve as anti-JCPyV drugs for treating PML.
JCPyV is closely related to two other polyomaviruses, SV40 and BK viruses (1) . A previous study demonstrated that inhibitors of topoisomerase strongly suppress SV40 DNA replication (18) , suggesting that topoisomerase I is required for efficient SV40 replication. CPT reportedly induces remarkable alternations of oligonucleotides containing the sequences of the topoisomerase I-induced and CPT-enhanced cleavage sites in SV40 DNA, whereas CPT11 interacts more weakly and in a different manner than CPT (10). It is possible that CPT11 forms a ternary Cell lysates 20 mL) were separated on a 12.5% SDS-PAGE gel, then transferred to PVDF membranes. The membranes were incubated with an anti-human polyomavirus JCPyV VP1 antibody, and then with a goat anti-mouse IgG H&L (HRP). Immunoreactive protein bands were visualized using a chemiluminescence imaging system. JCPyV VP1 was detected as a single band (42 kDa) in JCI cell lysate derived from all concentrations. complex with topoisomerase I and JCPyV DNA by binding reversibly at DNA cleavage sites.
In the present study, we used a culture system of JCI cells, which produce JCPyV, to assess the inhibitory effect of CPT11 for potential treatment of PML. It is likely that continuous production of JCPyV in a carrier culture of JCI cells is a sequential multi-step process in which newly-produced viruses can infect the remaining uninfected cells (11) . Thus, this culture system of JCI cells may provide a useful experimental model that mimics continuous propagation of JCV in the brains of patients with PML. We evaluated production of the VP1 antigen in JCI cells upon treatment with CPT11 using wstern blot analysis and immunocytochemical staining. CPT11 treatment of JCI cells led to a dose-dependent reduction in the amount of VP1 produced. In a previous study based on RT-PCR analysis, treatment with topotecan or b-lapachone induced marginal inhibition of virus propagation in JCI cells, which produce high titers of JCPyV (9) . In the present study, RT-PCR indicated that CPT11 significantly inhibits viral propagation in JCI cells. The IC 50 of CPT11 on JCPyV propagation was 73.4 nM, whereas the CC 50 of CPT11 in JCI cells was 10.7 mM because the IC 50 of CPT11 was much lower than the CC 50 . In addition, a comparative experiment showed that the inhibitory effect of CPT11 was stronger than those of topotecan or b-lapachone. A previous study indicated that CPTs, including topotecan, are substrates of ATP-binding cassette G2/breast cancer resistance protein, a drug efflux pump (19) , and are strongly expressed in brain microvascular endothelial cells of the blood brain barrier; thus, CPT11 is unlikely to be an effective drug candidate against PML unless the blood brain barrier is disrupted. A therapeutic strategy for maximizing efficacy under the constraint of minimal toxicity has been designed for CPT11 pharmacokinetics by using a mathematical model (20) . Further studies are required to improve the pharmacokinetics of CPT11 using such a drug delivery system in patients with PML. The large T antigen of JCPyV reportedly stimulates viral replication by inducing G 2 arrest in cells, and abrogation of G 2 arrest using a G 2 checkpoint inhibitor, such as caffeine, has demonstrated the potential of PML therapy (21) . In contrast, PLK1 belongs to a family of serine/threonine kinases that are involved in cell cycle regulation (22) , controlling several steps of the cell cycle, and is essential for G 2 /M transition and cell division. In a previous study, the active metabolite of CPT11 was found to down-regulate PLK1 (23) . Similarly, CPT11 may induce cell cycle alterations via down-regulation of cellular gene expression in IMR-32 and JCI cells, resulting in suppression of JCPyV replication. Global alterations in gene expression have been analyzed using cDNA microarrays after JCPyV infection (24) . In future, we plan to use cDNA microarrays to investigate whether cellular genes, including PLK1, are responsible for the inhibitory effect of CPT11 on JC virus replication. The present findings suggest that CPT11 may have 
